Haematologica, Vol 92, Issue 2, 271-272 doi:10.3324/haematol.10737
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arkenau, H.-T.
Right arrow Articles by Matutes, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arkenau, H.-T.
Right arrow Articles by Matutes, E.

Malignant Lymphomas

Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience

Hendrik-Tobias Arkenau*, Geoff Chong*, David Cunningham*,, David Watkins*, Bhawna Sirohi*, Ian Chau*, Andrew Wotherspoon°, Andy Norman#, Alan Horwich@, Estella Matutes^

* Department of Medicine, Royal Marsden Hospital, London and Sutton
° Department of Histopathology, Royal Marsden Hospital, London
# Department of Computing, Royal Marsden Hospital, Sutton
@ Department of Clinical Oncology, Royal Marsden Hospital, Sutton
^ Department of Hematology, Royal Marsden Hospital, Sutton, UK

Correspondence: David Cunningham, Department of Medicine, Royal Marsden Hospital, Downs Road, M2 5PT Sutton, Surrey, United Kingdom. Phone: international +44.0207.3528171, Fax: international +44.0208.6939414, E-mail: david.cunningham{at}rmh.nhs.uk

Novel, effective therapies are needed for peripheral T-cell non-Hodgkin’s lymphoma (PTCL). We treated 16 patients with a combination of gemcitabine, cisplatin and methylprednisolone (GEM-P). Three patients (19%) achieved a complete remission and eight (50%) a partial remission. GEM-P has encouraging efficacy with an acceptable toxicity profile in patients with PTCL.

Key words: T-cell lymphoma, PTCL, gemcitabine, cisplatin, methylprednisolone, GEM-P.




This article has been cited by other articles:


Home page
 Ann OncolHome page
P. L. Zinzani, F. Venturini, V. Stefoni, M. Fina, C. Pellegrini, E. Derenzini, L. Gandolfi, A. Broccoli, L. Argnani, F. Quirini, et al.
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
Ann. Onc., November 3, 2009; (2009) mdp508v1.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. M. Horwitz
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas
Hematology, January 1, 2008; 2008(1): 289 - 296.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Blood, October 1, 2007; 110(7): 2316 - 2323.
[Abstract] [Full Text] [PDF]